ClinicalTrials.gg
CompletedNCT02651662CLIO-1Updated Jun 2, 2026

A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies

A Phase 1 interventional study of cemiplimab and odronextamab in Relapsed/Refractory Aggressive B-Cell Lymphoma, sponsored by Regeneron Pharmaceuticals. Completed at 30 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-02.

Primary conditionLymphoma, B-CellRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, B-Cell
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Lymphoma, B-Cell.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
105
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 61 studies in Lymphoma, B-Cell with a site in Spain — 13 open to participants now, 31 under way, 10 of them phase 3. Lymphoma, B-Cell · Spain.

Enrollment
35th of 57
105 · median 140
Started
2016
with 2 others
Phase 1
17 of 61
5 open now
Registered
18th of 61
by date
Lead sponsor
3 of 61
Regeneron Pharmaceuticals

Among the 61 studies in Lymphoma, B-Cell with a site in Spain, this one is the 35th largest by enrollment of the 57 interventional ones that give a count, is one of 3 that started in 2016, is one of 17 in phase 1, and was the 18th registered.

Lymphoma, B-Cell

886 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

13 of the 61 studies in Lymphoma, B-Cell with a site in Spain are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 208 Lymphoma, B-Cell studies recruiting now, 128 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Lymphoma, B-Cell with a site in Spain, or all of them as a file.
02

Study summary

This study is researching a combination of 2 experimental drugs, referred to as "study drugs", called odronextamab (also known as REGN1979) and cemiplimab (also known as REGN2810). The study is focused on patients who have relapse/refractory aggressive B-cell lymphoma. The aim of the study is to see how safe and tolerable the study drugs are, and to define the recommended dose regimen for the combination with odronextamab.

This study is also looking at several other research questions, including:

  • What side effects may happen from taking the study drugs
  • How effective the study drugs are against the disease
  • How much study drug is in the blood at different times
  • Whether the body makes substances or protein called antibodies against the study drugs (that could make the drugs less effective or could lead to side effects)
03

Conditions studied

  • Relapsed/Refractory Aggressive B-Cell Lymphoma

Browse trials for

Keywords

  • B-Cell Non-Hodgkin Lymphoma (B-NHL)
04

In context

Lymphoma, B-Cell Reclassified

886 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

This study's enrollment of 105 is above the median of 34 across 773 interventional studies indexed under Lymphoma, B-Cell.

Browse Lymphoma, B-Cell studies →

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Compared within Lymphoma, B-Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Have documented CD20+ aggressive B-cell NHL that is either not responsive to or after at least 2 , for whom treatment with an anti-CD20 antibody may be appropriate. In addition, prior treatments should at least contain an anti-CD20 antibody and an alkylating agent.
  2. Must have at least 1 nodal lesion (≥1.5 cm), or at least one extranodal lesion with longest transverse diameter (LDi) greater than 1.0 cm, documented by diagnostic imaging (computed tomography [CT] or magnetic resonance imaging [MRI]).
  3. (ECOG) performance status ≤1
  4. Adequate bone marrow and hepatic function, as defined in the protocol
  5. Willing and able to comply with clinic visits and study-related procedures
  6. Provide signed

Key Exclusion Criteria:

  1. Primary central nervous system (CNS) lymphoma, or known or suspected CNS involvement by non-primary CNS NHL
  2. History of or current relevant CNS pathology, as described in the protocol
  3. Ongoing or recent (within 2 years) evidence of significant disease that required treatment with systemic treatments, which may suggest risk for immune-mediated adverse events (iAEs)
  4. Prior therapies, as described in the protocol
  5. Uncontrolled infection with (HIV), or infection or other uncontrolled infection
  6. Cytomegalovirus infection as noted by detectable levels on peripheral blood polymerase chain reaction (PCR) assay until the infection is well controlled.
  7. Known to both allopurinol and rasburicase
  8. Pregnant or breastfeeding women
  9. Women of , or men who are unwilling to practice highly effective prior to the initial dose/start of the first treatment, during the study, and for at least 6 months after the last dose, as defined in the protocol
  10. Patients prior diagnosis of hemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS)

Note: Other protocol-defined Inclusion/Exclusion criteria apply

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
105 participants (actual)

Study arms

  • Experimental
    Dose escalation phase

    Safety assessment of odronextamab in combination with cemiplimab and selection of recommended phase 2 dose (RP2D) regimen(s) for the combination of odronextamab and cemiplimab.

    Drug: cemiplimab · Drug: odronextamab

  • Experimental
    Dose expansion phase

    RP2D administration of the combination treatment.

    Drug: cemiplimab · Drug: odronextamab

Interventions

  • Administration via intravenous (IV) infusion. The dose(s) received will be according to dose level (DL) cohort assignment, as described in the protocol.

    Also known as: REGN2810, Libtayo

  • Administration IV infusion. The dose(s) received will be according to DL cohort assignment, as described in the protocol.

    Also known as: REGN1979

07

What researchers measure

Primary outcomes

  1. Incidence of dose limiting toxicities (DLTs) of cemiplimab in combination with odronextamab

    Time frame: Up to 28 days

  2. Incidence of treatment emergent adverse events (TEAEs) of cemiplimab in combination with odronextamab

    Time frame: Up to 18 months

  3. Severity of TEAEs of cemiplimab in combination with odronextamab

    Time frame: Up to 18 months

  4. Incidence of adverse events of special interest (AESIs) of cemiplimab in combination with odronextamab

    Time frame: Up to 18 months

  5. Severity of AESIs of cemiplimab in combination with odronextamab

    Time frame: Up to 18 months

Secondary outcomes

  1. Odronextamab and cemiplimab concentrations in serum

    Time frame: Up to 18 months

  2. Incidence of anti-drug antibodies (ADAs) to odronextamab and cemiplimab over time

    Time frame: Up to 18 months

  3. Titer of ADAs to odronextamab and cemiplimab over time

    Time frame: Up to 18 months

  4. Incidence of neutralizing antibodies (Nabs) to odronextamab and cemiplimab over time

    Time frame: Up to 18 months

  5. Titer of Nabs to odronextamab and cemiplimab over time

    Time frame: Up to 18 months

  6. Overall response rate as assessed by investigator

    Time frame: Up to 18 months

  7. Complete response (CR) rate as assessed by investigator

    Time frame: Up to 18 months

  8. Duration of response as assessed by investigator

    Time frame: Up to 18 months

08

Study locations

30 sites
  • Johns Hopkins University
    Baltimore, Maryland 21205, United States
  • Dana Farber/Harvard Cancer Center - PO box 849168
    Boston, Massachusetts 02215, United States
  • Harvard Medical School - Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Cancer & Hematology Centers of Western Michigan
    Grand Rapids, Michigan 49546, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Uniklinikum Salzburg (LKH) Universitatsklinik fur Innere Medizin III
    Salzburg, 5020, Austria
  • Medical University Vienna
    Vienna, 1190, Austria
  • University Hospital Frankfurt
    Frankfurt am Main, 60590, Germany
  • Universitatsklinikum Jena
    Jena, 7747, Germany
  • Universitatsklinikum Schleswig-Holstein, Campus Kiel
    Kiel, 24105, Germany
  • Soroka
    Beersheba, 84101, Israel
  • Hadassah Medical Center
    Jerusalem, 91200, Israel
  • Chaim Sheba Medical Center
    Ramat Gan, 5265601, Israel
  • Tel Aviv Sourasky Medical Center
    Tel Aviv, 64239, Israel
  • Pratia MCM Krakow
    Krakow, Malopolska 30-510, Poland
  • Uniwersyteckie Centrum Kliniczne
    Gdansk, Pomeranian Voivodeship 80-952, Poland
  • Pratia Onkologia Katowice
    Katowice, 40-519, Poland
  • Copernicus Memorial Hospital
    Lodz, 93-513, Poland
  • Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy Warszawa
    Warsaw, 02781, Poland
  • Hospital Universitario Marques de Valdecilla
    Santander, Cantabria 39008.0, Spain
  • Hospital Universitario Puerta de Hierro - Majadahonda
    Majadahonda, Madrid 28222, Spain
  • Hospital Universitario Quironsalud Madrid
    Pozuelo de Alarcón, Madrid 28223, Spain
  • Hospital Universitario Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, 08041, Spain
  • Institut Catala dOncologia (ICO Hospitalet)
    Barcelona, 08908, Spain
  • MD Anderson Cancer Center- Madrid
    Madrid, 28033, Spain
  • Hospital Universitario Fundacion Jimenez Diaz
    Madrid, 28040, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Clinico Universitario de Salamanca
    Salamanca, 37007, Spain
09

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2016 to primary completion in Apr 2026, 123 months.

Of 90 industry-sponsored phase 1 interventional studies under Lymphoma, B-Cell, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 81. This study's 123 months is above that.

Counting every sponsor, half of 207 studies reached it within 51 months; a quarter within 37 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2016
First posted
Jan 11, 2016
StartActual
Jan 11, 2016
Primary completionActual
Apr 29, 2026
CompletionActual
Apr 29, 2026
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02651662
Responsible party
Sponsor
First posted
Jan 11, 2016
Start date
Jan 11, 2016
Primary completion
Apr 29, 2026
Completion
Apr 29, 2026
Last update
Jun 2, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cemiplimab · Odronextamab

Start the discussion